US Stock MarketDetailed Quotes
PSNL Personalis
- 6.270
- +0.490+8.48%
Close Jan 2 16:00 ET
- 6.350
- +0.080+1.28%
Post 20:01 ET
531.03MMarket Cap-3.62P/E (TTM)
6.720High5.750Low1.26MVolume5.750Open5.780Pre Close8.02MTurnover2.82%Turnover RatioLossP/E (Static)84.69MShares7.20052wk High3.18P/B279.73MFloat Cap1.12052wk Low--Dividend TTM44.61MShs Float53.460Historical High--Div YieldTTM16.78%Amplitude0.891Historical Low6.372Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Personalis Stock Forum
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Thursday, 19th December at 9:00 am
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Mode...
Personalis and Tempus Expand Collaboration to Biopharma
Monday, 16th December at 8:00 am
Expanded collaboration to yield greater biopharma access to Personalis' MRD solution
Personalis, Inc. (NASDAQ: PSNL) and Tempus AI, Inc. (NASDAQ: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Soc...
📊⚡️📊
In a world where technological advancements continually reshape the landscape of healthcare, collaboration among industry leaders plays a pivotal role in accelerating innovation. A testament to this is the expanded collaboration between Personalis, Inc., a renowned leader in cancer genomics, and Tempus AI, Inc., a technology-driv...
📊⚡️📊
No comment yet